Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients
Mara Tynan(Georgetown University), Marc D. Schwartz(Guardia Civil), Lina Jandorf(Icahn School of Medicine at Mount Sinai), Gillian W. Hooker(National Institutes of Health), Sarah A. Kelleher(Icahn School of Medicine at Mount Sinai), Elizabeth Poggi(Georgetown University), Scott P. Kelly(Pfizer (United States)), Claudine Isaacs(Georgetown University), Suzanne C. O’Neill(Georgetown University), Heiðdís Valdimarsdóttir(Reykjavík University), Jessica Heinzmann(Atlantic Health System), Beth N. Peshkin(Georgetown University), Shawna C. Willey(Georgetown University), Rachel Nusbaum(Icahn School of Medicine at Mount Sinai)
Cited by 13
Related Papers
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy
|New England Journal of Medicine|2012|1k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Screening by Chest Radiograph and Lung Cancer Mortality
|JAMA|2011|659
The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening
|Preventive Medicine|2003|495